Vaxcyte, Inc.
PCVX
$30.65
$1.535.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 24.22% | 7.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.90% | -8.54% | |||
| Operating Income | -15.90% | 8.54% | |||
| Income Before Tax | -32.93% | 19.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.93% | 19.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.93% | 19.87% | |||
| EBIT | -15.90% | 8.54% | |||
| EBITDA | -15.32% | 8.90% | |||
| EPS Basic | -21.61% | 24.04% | |||
| Normalized Basic EPS | -21.57% | 24.06% | |||
| EPS Diluted | -21.61% | 24.04% | |||
| Normalized Diluted EPS | -21.57% | 24.06% | |||
| Average Basic Shares Outstanding | 9.30% | 5.49% | |||
| Average Diluted Shares Outstanding | 9.30% | 5.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||